Today: 18 July 2026
Browse Category

Biotechnology 19 October 2025 - 30 October 2025

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecastinvesting.com. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly $0.79 loss expected. Management immediately lifted the full-year sales outlook to $965–970 millioninvestors.guardanthealth.com, up from $915–925M previously. As a result, GH stock jumped nearly 30% in morning trading on Oct. 30seekingalpha.comreuters.com. This breakout comes on top of an already huge run – shares were up over 210% year-over-year before the earnings releaseinvesting.com.
30 October 2025
··
Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience’s share price has been on a wild ride in 2025, mostly downhill. The stock now hovers around 40 cents, down from the mid-$2 range a year agofintel.io. In fact, HBIO has lost nearly 84% of its value year-over-yearfintel.io, an astonishing collapse that reflects both company-specific struggles and the broader market rout in small-cap biotech names. Shares cratered to an intraday low of $0.28 in mid-2025 amid intense selling pressureinvesting.com, before staging a modest rebound. Even after some recovery, HBIO remains deep in penny stock territory, a far cry from its 52-week high of $3.27investing.com.
30 October 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener, the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts.
30 October 2025
····
Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR therapy NTLA-2001 due to a serious adverse event ts2.tech. The immediate market reaction was brutal: NTLA stock plunged ~44% in pre-market trading and went on to close around $14.79 ts2.tech marketbeat.com. In dollar terms, shares that traded near $25–26 late last week collapsed into the low-teens, vaporizing over $1 billion in market value in just hours ts2.tech.
28 October 2025
···
Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Co-Diagnostics’ stock price erupted on Monday after the company unveiled a strategic joint venture in the Middle East. Shares of the small-cap diagnostics firm opened around $0.59 and quickly soared, at one point up 133% to about $0.82 by mid-morningbenzinga.com. The surge only intensified as trading progressed – by late morning the stock was up 148% and still climbing, prompting a wave of retail trader excitement onlinemenafn.com. CODX ultimately closed at $1.07, marking a stunning +206% one-day gainfinance.yahoo.com. For context, the stock had ended the prior trading day at roughly $0.35nasdaq.com, and was down over 70% in the past year before this week’s newstickernerd.com.
27 October 2025
··
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR treatment nexiguran ziclumeran due to a serious adverse event reuters.com. A patient in the Phase 3 MAGNITUDE study – which tests NTLA-2001 in transthyretin amyloidosis patients with cardiomyopathy – experienced Grade 4 elevations in liver enzymes and bilirubin after receiving the one-time gene therapy reuters.com ca.investing.com. This met the trial’s pre-specified safety threshold for a mandatory pause.
27 October 2025
···
CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics’ stock has been on a wild ride this year. As of midday October 27, CRSP hovered around $67 per share – off its highs but still up dramatically from early 2025 levels Genengnews. Over the past six months, the stock jumped 83% Genengnews. Just this month, shares spiked 5% in three days after the company reported positive gene-editing data in a new therapy, briefly topping $71 Genengnews. Year-to-date, CRSP had nearly doubled as of early October ts2.tech, reflecting growing investor enthusiasm for gene-editing breakthroughs.
27 October 2025
··
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech.
27 October 2025
·····
Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion’s narrative centers on its AI-enhanced drug discovery platform. Founded in 2013 in Salt Lake City, Recursion has spent years building RecursionOS, a giant database of cellular images and chemical data powered by machine learning biotechhealthx.com. The company invested heavily in bio-automation infrastructure to train AI models on billions of data points. Its strategy is twofold: use this tech to generate proprietary drug candidates while partnering with pharma giants to co-develop new drugs. As one biotech newsletter notes, Recursion “has focused on fewer but more strategically important deals” with big pharma, securing hefty upfronts and milestones, while advancing its own pipeline in parallel biotechhealthx.com. The recent Exscientia merger and open-sourcing of the Boltz-2 model underscore its AI ambitions ts2.tech ts2.tech.
26 October 2025
···
NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis’s Oct. 24, 2025 announcement of FDA 510 clearance for its PENFS device immediately grabbed market attention. The clearance authorizes use in adults for functional abdominal pain associated with FD and nausea, a segment previously lacking any approved device treatmentinvesting.com. Investing.com and other outlets confirm this milestone — noting it’s “the first FDA clearance or approval” for an adult FD treatmentinvesting.com. In pre-market trading on Oct. 24, NRXS shares jumped on the news, reflecting relief that FDA evidence support could be extended to adultsinvesting.com. Management expects this expansion to “drive substantial top-line growth” as the therapy can now reach millions of adult patients along with children.
24 October 2025
··
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run. The stock has surged ~28% on Oct 23 after a prior drop. Recent catalysts include completion of a 1-year Phase 3 trial showing robust, sustained efficacy revivapharma.com, and plans for an FDA meeting in Q4 2025 toward a 2026 NDA revivapharma.com. Reviva also raised capital via equity offerings to fund its CNS pipeline. Analysts remain extremely bullish – consensus is “Strong Buy” with an average 12‑month target around $6.25 investing.com investing.com. By comparison, MarketBeat reports a mean $4.86 target marketbeat.com. In the broader biotech space, industry news and deals are driving rallies.
24 October 2025
···
Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta’s Oct. 24 announcement ignited optimism. According to the official press release, Anemocyte will incorporate Genenta’s clinically validated LVV plasmid DNA platform into its production pipeline investing.com. “By making our clinically validated LVV plasmid DNA technology platform available to Anemocyte and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry,” said CEO Pierluigi Paracchi investing.com. Anemocyte’s CEO Marco Ferrari added that the deal ensures customers have access to “a robust, well-established platform” for cutting-edge cell therapies investing.com. In effect, the partnership helps Genenta and its clients secure high-quality plasmid DNA from R&D through GMP stages, a critical bottleneck for gene therapy developers stocktitan.net investing.com.
24 October 2025
··
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies, so the positive data are significant. According to the company and press accounts, the trial met its primary endpoint with a statistically significant jump in progression-free survival biospace.com. Patients on ozekibart lived a median 5.52 months without progression versus 2.66 months on placebo – a 52% reduction in the risk of progression or death biospace.com. All patient subgroups saw benefit, and secondary measures like disease-control rate and quality-of-life scores also favored ozekibart biospace.com.
24 October 2025
··
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics globenewswire.com. – Price: ~$30 per share ts2.tech. – Sector: Biotechnology globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy and Orphan Drug designations to Beam’s lead programs globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside.
21 October 2025
··
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range stockanalysis.com. Trading volume is light, and the stock’s beta indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average and 200-day average suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average.
21 October 2025
···
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the dayfinviz.com. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart – the stock’s 50-day moving average recently rose above its 200-day averagefinviz.com, a technical signal often seen as confirmation of a positive trend reversal. Zacks noted that BEAM had rallied ~6.8% over the prior four weeks leading into this golden-cross eventfinviz.com, helping shift its Zacks Rank to #2. The sharp Monday jump may have been fueled by momentum traders reacting to these technicals and upbeat analyst commentary, as well as broader sector tailwinds.
20 October 2025
·····
Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intradaymarketbeat.com, an approximately 40–50% single-day leap, before settling near a record high close. This surge marked a new 52-week high of $81.56marketbeat.com and lifted Celcuity’s market capitalization above $2.2 billioninvesting.com. The stunning rally came on unusually heavy trading volume as investors rushed to buy shares, propelled by news from a major cancer conference.
20 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL’s stock price exploded after the company announced a strategic alliance with Samsung on October 16. Under the deal, Samsung C&T will invest $110 million in GRAIL and become the exclusive distributor of the Galleri multi-cancer blood test in South Korea, with rights to expand into Japan and Singaporets2.tech. Samsung Electronics is also participating and plans to explore AI and health-data collaborations with GRAILts2.tech. This marks a major vote of confidence from one of Asia’s largest conglomerates. The partnership is expected to close by early 2026 and gives GRAIL a powerful commercialization partner in key Asian marketstradingview.com.
20 October 2025
···
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech. In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake in SLS on Oct. 18 ts2.tech, and other funds like Vanguard and Marshall Wace added millions of shares in Q2 quiverquant.com. On the drug-development front, Sellas’s lead AML immunotherapy is in a Phase 3 AML trial, which recently passed an interim safety review ir.sellaslifesciences.com; SLS’s CDK9 inhibitor reported 44% response in a Phase 2 relapsed AML trial ir.sellaslifesciences.com and just showed statistically significant survival gains in a rare T-cell leukemia model ts2.tech ir.sellaslifesciences.com. The company will hold a virtual R&D Day on Oct. 29, 2025 to update investors on these AML programs ts2.tech, and final REGAL results are expected by late 2025 – potential near-term catalysts. Analysts are optimistic: Maxim Group reiterated a “Buy” and $7.00 12-month price target ts2.tech, and the consensus target implies ~220% upside ts2.tech investing.com. Sellas ended Q2 2025 with ~$25M cash on hand ts2.tech and raised another $23.6M through warrant exercises in Sept. 2025 ts2.tech to fund its trials. Overall,
20 October 2025
··
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53marketbeat.com, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursdayir.vikingtherapeutics.com. This marks a dramatic recovery from mid-August, when VKTX plunged over 40% in one day following a crucial trial announcementts2.tech. Back then, Viking had unveiled results from a Phase 2 study of its oral obesity pill that missed investor expectations, triggering a sharp selloff. Since that rout, the stock has climbed back as optimism returns ahead of key catalysts. Heavy trading activity underscores the renewed interest – on Oct. 15, nearly 22,823 call options on VKTX traded, including a burst of bullish bets at the $50 January strikets2.tech. This elevated options volume suggests traders positioning for potential upside moves.
19 October 2025
··
1 … 14 15 16 17 18 19
Go toTop